GlassScriptPhysician profile
Katherine A Witherington
NPI 1467417147
$931.15
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $931.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $201.49 | 2019 | |
| Pfizer INC. | $128.93 | 2019 | |
| Novo Nordisk INC | $124.83 | 2019 | |
| Amgen INC. | $119.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.69 | 2019 | |
| Amarin Pharma, INC. | $45.50 | 2019 | |
| Glaxosmithkline, LLC. | $39.74 | 2019 | |
| Sanofi-Aventis U.S. LLC | $35.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.64 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.87 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.68 | 2019 | |
| Gilead Sciences, INC. | $22.74 | 2019 | |
| Daiichi Sankyo INC. | $14.63 | 2019 | |
| Abbvie INC. | $12.82 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.61 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $12.33 | 2019 | |
| Collegium Pharmaceutical, INC. | $11.76 | 2019 | |
| Sanofi Pasteur INC. | $10.97 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Witherington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.